U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H29N7O3.ClH
Molecular Weight 487.982
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LX-7101 HYDROCHLORIDE

SMILES

Cl.CN(C)C(=O)OC1=CC(NC(=O)C2(CN)CCN(CC2)C3=NC=NC4=C3C(C)=CN4)=CC=C1

InChI

InChIKey=ZQRGQMCNRINKRN-UHFFFAOYSA-N
InChI=1S/C23H29N7O3.ClH/c1-15-12-25-19-18(15)20(27-14-26-19)30-9-7-23(13-24,8-10-30)21(31)28-16-5-4-6-17(11-16)33-22(32)29(2)3;/h4-6,11-12,14H,7-10,13,24H2,1-3H3,(H,28,31)(H,25,26,27);1H

HIDE SMILES / InChI
Molecular Formula C23H29N7O3
Molecular Weight 451.5215
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25589936

LX-7101 (Lexicon Pharmaceuticals) was advanced to Phase-I clinical trials for treatment open-angle glaucoma or ocular hypertension. This drug is a potent inhibitor of LIM-kinase 2 (LIMK2) kinase and inhibits to less extent LIMK1 and Rho-associated protein kinase 2 (ROCK2).

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 4.3 nM [IC50]
Inhibitor
8297
 32.0 nM [IC50]
Inhibitor
8297
 32.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase I
428
Unknown

Approved Use

Unknown
Primary
Phase I
428
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P008U31
https://www.1pchem.com/search?query=1P008U31
AChemBlock
M15681
http://www.achemblock.com/catalogsearch/result/?q=M15681
ApexBio Technology
B5863
https://www.apexbt.com/catalogsearch/result/?q=B5863
AstaTech
C14316
http://astatechinc.com/CPSResult.php?CRNO=C14316
BLD Pharm
BD629971
http://www.bldpharm.com/search/Search.html?keyword=BD629971
Cayman Chemical
21209
http://www.caymanchem.com/app/template/Product.vm/catalog/21209
Chem Scene
CS-5103
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-5103
Excenen
EX-A2288
http://www.excenen.com/searchresultlist.php?id=EX-A2288
MedChem Express
HY-12659
https://www.medchemexpress.com/search.html?q=HY-12659&ft=&fa=&fp=
MolPort
MolPort-044-561-838
https://www.molport.com/shop/molecule-link/MolPort-044-561-838
MolPort
MolPort-046-416-915
https://www.molport.com/shop/molecule-link/MolPort-046-416-915
Molnova
M10664
https://www.molnova.com/en/serch-list.html?keywords=M10664
MuseChem
I000697
https://www.musechem.com/product/I000697.html
MuseChem
R066798
https://www.musechem.com/product/R066798.html
ShangHai Biochempartner
BCP000294
http://www.biochempartner.com/search_BCP000294
ShangHai Biochempartner
BCP02298
http://www.biochempartner.com/search_BCP02298
eMolecules
72973106
https://orderbb.emolecules.com/search/#?query=72973106
eMolecules
93437748
https://orderbb.emolecules.com/search/#?query=93437748
mcule
MCULE-8096869004
https://mcule.com/MCULE-8096869004/
PubMed

PubMed

TitleDatePubMed
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
2015 Jan 8
Design, synthesis and biological characterization of selective LIMK inhibitors.
2015 Sep 15
Patents

Patents

08193202
2
08450332
2
08735408
2
20090264450
2
20120122898
2
20120329818
2
8193202
2
8450332
2
8735408
2
JP2013541588A
2
WO2009131940A1
2
WO2012061565A1
2
WO2015150337A1
2

Sample Use Guides

In Vivo Use Guide
Low dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye High dose LX7101: Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye).
Route of Administration: Other
In Vitro Use Guide
In vitro assay was used to identify LIMK and ROCK inhibitors. For kinetic studies, the final LX7101concentrations varied from 0 to 100 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 02:07:41 GMT 2023
Edited
by admin
on Sat Dec 16 02:07:41 GMT 2023
Record UNII
S5G8WJ39X9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LX-7101 HYDROCHLORIDE
Common Name English
LX7101 HYDROCHLORIDE
Code English
LX-7101 HCL
Code English
CARBAMIC ACID, N,N-DIMETHYL-, 3-(((4-(AMINOMETHYL)-1-(5-METHYL-7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-4-PIPERIDINYL)CARBONYL)AMINO)PHENYL ESTER, HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
CAS
1374644-80-0
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
NON-SPECIFIC STOICHIOMETRY
FDA UNII
S5G8WJ39X9
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
PRIMARY
PUBCHEM
56962368
Created by admin on Sat Dec 16 02:07:41 GMT 2023 , Edited by admin on Sat Dec 16 02:07:41 GMT 2023
PRIMARY
Related Record Type Details
Structure of LX-7101
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of LX-7101
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966